Skip to content

Major Depressive Disorders”: Recent Developments and Clinical Application

2019 APA Scientific Conference

Please click "Next" if you did not attend this session
1000%
The session met the stated learning objectives:
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
Provide an overview of the glutamate system in the
brain and how it is impacted by ketamine;
Present clinical results establishing the rapid onset of action of ketamine in treatment-resistant major
depressive episodes; and
Describe the clinical effectiveness of new emerging
therapies in MDD.
Please rate the following on a scale of 1 to 5
(1 - strongly disagree and 5 - strongly agree):
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
The session was educationally relevant.
The presenter was educationally effective.
The session provided interactive opportunities.
The session provided opportunities to identify and/or reflect on what was learned and its potential impact on my practice
Please rate the following on a scale of 1 to 5
(1 - strongly disagree and 5 - strongly agree):
Strongly disagree
Disagree
Somewhat disagree
Neither agree or disagree
Somewhat agree
Agree
Strongly agree
The session and presenter did NOT have commercial or other inappropriate bias.
Please provide any other comments you would like to share: